Cytovance Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and microbial biologics, has appointed Ping Zhang as chief executive officer.   In his role as CEO, Zhang provides oversight in the development and execution of the company’s business strategies in the contract manufacturing industry. He holds a Master of Business Administration and serves on the board of other subsidiaries within the Hepalink Group.   Zhang has over 30 years of e...